Teleflex Incorporated (NYSE:TFX) Given Consensus Recommendation of “Hold” by Brokerages

Teleflex Incorporated (NYSE:TFX) has earned an average recommendation of “Hold” from the eleven research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $182.63.

Several research analysts have issued reports on the stock. Bank of America lowered shares of Teleflex from a “neutral” rating to an “underperform” rating and lowered their price target for the stock from $235.00 to $140.00 in a report on Tuesday, March 4th. Morgan Stanley lowered their price target on shares of Teleflex from $275.00 to $191.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. Raymond James lowered shares of Teleflex from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Wells Fargo & Company lowered their price target on shares of Teleflex from $214.00 to $146.00 and set an “equal weight” rating for the company in a report on Friday, February 28th. Finally, Truist Financial lowered their price target on shares of Teleflex from $200.00 to $149.00 and set a “hold” rating for the company in a report on Monday, March 3rd.

Institutional Trading of Teleflex

Several hedge funds have recently modified their holdings of the stock. Janney Montgomery Scott LLC grew its position in Teleflex by 0.4% in the 3rd quarter. Janney Montgomery Scott LLC now owns 15,332 shares of the medical technology company’s stock valued at $3,792,000 after purchasing an additional 65 shares during the period. Robeco Institutional Asset Management B.V. acquired a new stake in Teleflex in the 3rd quarter valued at $687,000. QRG Capital Management Inc. acquired a new stake in Teleflex in the 3rd quarter valued at $509,000. Principal Financial Group Inc. grew its position in Teleflex by 2.7% in the 3rd quarter. Principal Financial Group Inc. now owns 80,409 shares of the medical technology company’s stock valued at $19,887,000 after purchasing an additional 2,086 shares during the period. Finally, Capital Performance Advisors LLP acquired a new stake in Teleflex in the 3rd quarter valued at $54,000. Institutional investors own 95.62% of the company’s stock.

Teleflex Stock Up 2.9 %

Shares of NYSE TFX opened at $140.24 on Monday. The company has a 50 day simple moving average of $171.13 and a 200 day simple moving average of $201.04. The firm has a market cap of $6.50 billion, a PE ratio of 27.88, a price-to-earnings-growth ratio of 1.73 and a beta of 1.21. Teleflex has a 1 year low of $128.55 and a 1 year high of $249.90. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.86 by $0.03. The business had revenue of $795.40 million during the quarter, compared to analyst estimates of $813.24 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. On average, research analysts forecast that Teleflex will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Friday, March 7th will be paid a $0.34 dividend. The ex-dividend date is Friday, March 7th. This represents a $1.36 annualized dividend and a dividend yield of 0.97%. Teleflex’s dividend payout ratio is currently 95.77%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.